| Popis: |
Background Hyperuricemia is common and along with comorbidities, is increasing in prevalence. Though often asymptomatic and hence, under diagnosed, it may be associated with subclinical urate deposition. Ultrasound (US) imaging can detect urate deposition in individuals with asymptomatic hyperuricemia (ASU). Objectives To evaluate the association of comorbidities with urate deposition via US in ASU. Methods ASU was defined as serum urate (sUA) >6 mg/dl; sUA Results Of 95 predominantly non-Hispanic Blacks (mean age 59.7 years, BMI ~32 kg/m2), ASU subjects (n=71, median sUA=8.0) were older men, with more frequent HTN, CVD, CKD, alcohol ingestion versus controls. In multivariate analyses adjusting for demographic characteristics, BMI, CKD, and alcohol use were positively associated with sUA >6 mg/dl; while HTN, CVD, and CKD were positively associated with sUA >8 mg/dl. Adjusting for comorbidities, sUA >8 mg/dl was significantly associated with urate deposition at knee (OR=3.20; p=0.03), quadriceps and Achilles tendons (OR=4.14; p 6 mg/dl alone, however, did not predict urate deposition. Conclusions Presence of HTN, CVD and CKD are associated with higher levels of sUA and increases the risk of urate deposition in ASU patients. Identifying a subset of ASU patients that may benefit from urate lowering therapy requires further stratification and long term follow up for incident gouty arthritis in order to alter current urate lowering treatment guidelines. Disclosure of Interest G. Kerr Grant/research support from: Ardea, Grunenthal, Horizon, S. Dowell Grant/research support from: Horizon, A. Wells: None declared, R. Haddad: None declared, P. DeMarco: None declared, J. Joseph: None declared, J. Ude: None declared, S. Hochberg: None declared, J. Huang: None declared, D. Nashel: None declared |
